Clinical evaluation is crucial in the clinical diagnosis, treatment, and prognosis prediction in patients with traumatic brain injury (TBI). However, the existing evaluation systems are not perfect, because many factors are not taken into account, for example, there is a lack of molecular diagnostic criteria for evaluating patients with TBI. We attempt to collect the patient's clinical data and combine it with neuroimaging, as well as molecular biomarkers generated by single-cell sequencing to assess their neurological status and outcome. The clinical and molecular data collection and analysis will be helpful to evaluate the patient's neurological condition and predict the patient's outcome more accurately.
CT/MRI confirmed TBI;
The time from onset to the emergency room (ER ) within 12h;
The systolic pressure (SBP) ≥ 90 mmHg;
Patients willing to participate in this study with signed informed consent.
Patients who are not suitable for surgery (GCS score 3 points, dilated and fixed bilateral pupils, pregnant women, etc.);
Pre-injury life expectancy ≤ 1 year (malignant tumor);
Previous history of acute myocardial infarction, abnormal immune function, and blood-related diseases;
without informed consent.
patients with traumatic brain injury (TBI) or other brain diseases (gliomas, meningiomas, schwannoma) who are treated surgically
Case-control
Prospective
No intervention
Other interventionpatients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
Accurate assessment of patients' neurological condition
Using a regression model to explore the relationship between a patient's neurological condition and clinical and molecular biological data
Predicting patients' outcome accurately
Using a regression model to explore the relationship between a patient's prognosis and clinical and molecular biological data
Click on the lead sponsor to view all of their trials.
